Breast cancer requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, chemotherapies, and targeted therapies. Treatment decisions are influenced by disease stage,…
The drug treatment of prostate cancer has evolved rapidly over the last few years—the metastatic castrate-resistant prostate cancer (mCRPC) setting has become crowded and competitive following…
Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansions…
Tens of thousands of Brazilian and Mexican men are diagnosed with prostate cancer every year. In recent years, there have been multiple clinical advances in the field, with new therapies offering…
Gastric and gastroesophageal junction (GEJ) adenocarcinoma is characterized by poor prognosis. Japan has the highest incidence of gastric and GEJ adenocarcinoma among the markets under study,…
Consolidation within the oncology provider community, including hospital acquisitions of oncology practices and oncology practices joining together, is changing the dynamics in the relationship…
Colorectal cancer (CRC) affects several thousands of people in Brazil and Mexico. Once it metastasizes, the only available therapeutic options are premium-priced targeted agents and chemotherapy…
Biomarker-driven prescribing in oncology is playing an increasingly important role in various diseases, from indications in which its use is well entranced such as non-small-cell lung cancer (NSCLC…
Pancreatic cancer remains a deadly disease with limited treatment options. The current standards of treatment are mFOLFIRINOX and gemcitabine + Abraxane. Market growth over the forecast period to…
The prevalence of chronic pain associated with numerous indications (e.g., osteoarthritis, cancer) and of idiopathic origin (e.g., chronic back pain) continues to increase throughout the EU5. The…
Biomarker-driven prescribing plays an increasingly prominent role in key oncology indications. The choice of therapy for breast cancer has long been informed by the presence of key biomarkers, and…
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…
Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—including those for biomarker-…
Seven premium-priced therapies—Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza—are approved in the United States for metastatic colorectal cancer. Therefore, medical…
Genomic aberration status, histology, performance status, and stage of disease are key factors that influence the treatment of non-small-cell lung cancer (NSCLC). The characterization of biomarker-…